Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05768373 · ClinicalTrials.gov registry record · NA
A Comparison Study of Hypersensitivity Treatment
A NA study of Dentin Hypersensitivity, sponsored by Solventum US.
- Completed
- Registry status
- NA
- Development phase
- 101
- Enrollment target
- 1
- Study location
NCT05768373: Completed NA study of Dentin Hypersensitivity, sponsored by Solventum US.
NCT05768373 is a NA study of Dentin Hypersensitivity that has completed, run by Solventum US. The registered enrollment target is 101 participants, below the 363-participant average among 4 other Dentin Hypersensitivity trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05768373, a NA study of Dentin Hypersensitivity, has completed, sponsored by Solventum US.
- COMPLETED
- Registry status
- NA
- Development phase
- 101 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the effect of 3M™ Clinpro™ Fluoride Aqueous Solution (experimental) on Dentin Hypersensitivity (DHS) in comparison to 3M™ Vanish™ (commercialized, control\] in patients who have DHS. Participants will be asked to complete the following activities: Undergo a pre-treatment washout period for 3- to 6-weeks (± 4 days) post-enrollment. During this time, the Subject is to only use the provided oral hygiene products. Hypersensitivity will be assessed prior to (baseline) and immediately after sample application. Subject will be asked to come to the facility for hypersensitivity assessments at 24 hours, 7 days, and 30 days after the treatment visit. Researchers will compare 3M™ Clinpro™ Fluoride Aqueous Solution to 3M™ Vanish™ to evaluate if the effect of Clinpro™ on DHS treatment is non-inferior to Vanish™.
Primary Outcome
Change in sensitivity as assessed using a Visual Analog Scale (VAS, 0 - 100 mm) immediately after exposure to air stimulus relative to baseline. The VAS consists of a 100mm line, with two extremes being 0 mm (no pain) and 100 mm (worst pain). Higher scores mean a worse outcome.
Conditions Studied
Interventions
- DEVICE 3M™ Clinpro™ Fluoride Aqueous Solution
- DEVICE 3M™ Vanish™
Study Locations (1)
California
- LOMA LINDA UNIVERSITY, School of Dentistry - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2023-07-14 |
| Phase | NA |
What the finished NCT05768373 record still lists
NCT05768373 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 363-participant average among 4 other Dentin Hypersensitivity trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Dentin Hypersensitivity appearing as the primary indexed condition, and to 2 interventions - of which 3M™ Clinpro™ Fluoride Aqueous Solution is the first listed.
NCT05768373 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05768373 about?
NCT05768373 is a clinical study titled "A Comparison Study of Hypersensitivity Treatment". The goal of this clinical trial is to evaluate the effect of 3M™ Clinpro™ Fluoride Aqueous Solution (experimental) on Dentin Hypersensitivity (DHS) in comparison to 3M™ Vanish™ (commercialized, control\] in patients who have DHS. Participants will be asked to complete the following activities: Und...
What is the current status of trial NCT05768373?
This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2023-04-04. Estimated completion is 2023-07-14.
What conditions does trial NCT05768373 study?
This clinical trial studies the following conditions: Dentin Hypersensitivity.
What interventions are being tested in trial NCT05768373?
The interventions under investigation include: 3M™ Clinpro™ Fluoride Aqueous Solution (DEVICE), 3M™ Vanish™ (DEVICE).
Who is sponsoring clinical trial NCT05768373?
This trial is sponsored by Solventum US, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05768373 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dentin Hypersensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Tooth Whitening and Dentin Hypersensitivity Effectiveness of Two Experimental Toothpastes
RECRUITING · NA
-
A Clinical Study to Assess the Effects of Various Dentifrice Technologies on Dentinal Hypersensitivity
COMPLETED · NA
-
Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice
RECRUITING · Phase 3
-
A Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI